Characterization of glutathione conjugates of the remoxipride hydroquinone metabolite NCQ-344 formed in vitro and detection following oxidation by human neutrophils.
Remoxipride is an atypical antipsychotic displaying selective binding to the dopamine D2 receptor. Several cases of aplastic anemia led to the withdrawal of remoxipride from the market in December 1993. The remoxipride metabolite NCQ-344 is a hydroquinone while the structural isomer NCQ-436 is a catechol, both of which have been suggested to be capable of forming a reactive para- and ortho-quinone, respectively. Recently, these two remoxipride metabolites were shown to induce apoptosis in human bone marrow progenitor cells. Furthermore, NCQ-344 also caused necrosis of these cells unlike NCQ-436. Although NCQ-344 has been detected in plasma of humans dosed with remoxipride, to date, no experimental evidence for the formation of the corresponding para-quinone has been obtained. Here, we report the detection of three glutathione (GSH) conjugates of NCQ-344 in vitro that were formed following a chemical reaction and characterized by tandem mass spectrometry and for a cyclized conjugate additionally with derivatization and deuterium exchange. In contrast, NCQ-436 did not form a GSH conjugate. Hypochlorous acid oxidized NCQ-344 to the para-quinone while NCQ-436 was resistant to oxidation. Upon incubation with NCQ-344, stimulated human neutrophils produced from 2- to 5-fold greater amounts of glutathione conjugates than unstimulated neutrophils. Ab initio calculations on these remoxipride metabolites indicated that the reaction leading to the respective quinone was spontaneous for the para-quinone (e.g., from NCQ-344) while ortho-quinone (e.g., from NCQ-436) formation was not. These results demonstrate that NCQ-344 is capable of facile formation of a reactive para-quinone capable of reacting with GSH and may rationalize previous findings regarding the biological effects observed in vitro with these two remoxipride metabolites.
Erve
John C L
JC
Departments of DMPK & Bioanalytical Chemistry and Computational Chemistry, AstraZeneca R&D, S-151 85 Södertälje, Sweden.
Svensson
Mats A
MA
von Euler-Chelpin
Hans
H
Klasson-Wehler
Eva
E
D014150:Antipsychotic Agents / Q000009:adverse effects*; D017209:Apoptosis / Q000187:drug effects; D018929:Cell Culture Techniques; D005978:Glutathione / Q000378:metabolism*; D006801:Humans; D006873:Hydroquinones / Q000737:chemistry*; D013058:Mass Spectrometry; D009504:Neutrophils / Q000737:chemistry; D010084:Oxidation-Reduction; D011809:Quinones / Q000737:chemistry; D017330:Remoxipride / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000737:chemistry*
D014150:Antipsychotic Agents; D006873:Hydroquinones; C112341:NCQ 344; D011809:Quinones; D017330:Remoxipride; D005978:Glutathione